Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation

Clinical Transplantation

Volumn 11, Issue 5 I, 1997, Pages 432-437

  Falagas, Matthew E ^a   Snydman, David R ^a,b   Ruthazer, Robin ^a   Griffith, John ^a   Werner, Barbara G ^a   Freeman, Richard ^a   Rohrer, Richard ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

Cytomegalovirus; Cytomegalovirus immune globulin (CMVIG); Prophylaxis; Survival

Indexed keywords

CYTOMEGALOVIRUS ANTIBODY; LYMPHOCYTE ANTIBODY; METHYLPREDNISOLONE SODIUM SUCCINATE;

ADULT; ARTICLE; BLOOD TRANSFUSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DATA ANALYSIS; DEMOGRAPHY; DOUBLE BLIND PROCEDURE; FEMALE; FOLLOW UP; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY FUNCTION TEST; LIVER FUNCTION TEST; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MULTICENTER STUDY; OPERATION DURATION; ORAL DRUG ADMINISTRATION; POSTOPERATIVE COMPLICATION; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL;

ADOLESCENT; ADULT; ANTILYMPHOCYTE SERUM; BLOOD TRANSFUSION; BOSTON; CHILD; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNIZATION, PASSIVE; IMMUNOGLOBULINS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY; LIVER; LIVER CIRRHOSIS, BILIARY; LIVER TRANSPLANTATION; LONGITUDINAL STUDIES; MALE; METHYLPREDNISOLONE HEMISUCCINATE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLACEBOS; PROPORTIONAL HAZARDS MODELS; SURVIVAL RATE; TIME FACTORS;

EID: 0030731032     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (38)

1. STRATTA RJ, SHAEFFER MS, MARKIN RS, et al. Cytomegalovirus infection and disease after liver transplantation. Digestive Diseases and Sciences 1992: 37: 673.
2. RUBIN RH. Infection in the organ transplant recipient. In: RUBIN RH, YOUNG LS (eds). Clinical approach to infection in the immunocompromized host, 3rd edn. New York: Plenum Medical Book, 1994: pp. 647-59.
3. WIESNER RH, MARIN E, PORAYKO MK, STEERS JL, KROM RAF, PAYA CV. Advances in liver transplantation. Gastroenterology Clinics of North America 1993. 22(2): 351.
4. HO M. Cytomegalovirus infection after organ transplantation: Sources of virus including blood. In Ho M., ed., Cytomegalovirus: Biology and Infection. 2nd edn. Plenum, New York: Plenum NY, 1991, pp. 252-256.
5. REINKE P, FIETZE E, ODE-HAKIM S, et al. Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet 1994: 344: 1737.
6. GRATTAN MT, MORENO-CABRAL CE, STARNES VA, OYER PE, STINSON EB, SHUMWAY NE. Cytomegalovirus infection is associated with cardiac allograft rejection and atherosclerosis. J Am Med Assoc 1989: 261: 3561.
7. RAND KH, POLLARD RB, MERIGAN TC. Increased pulmonary superinfections in cardiac-transplant patients undergoing primary cytomegalovirus infection. N Engl J Med 1978;298(17): 951-953.
8. GORENSEK MJ, STEWART RW, KEYS TF, MCHENRY MC, BABIAK T, GOORMASTIC M. Symptomatic cytomegalovirus infection as a significant risk factor for major infections after cardiac transplantation. J Infect Dis 1988: 158: 884.
9. COLLINS LA, SAMORE MH, ROBERTS MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Inf Dis 1994: 170: 644.
10. PAYA CV, WIESNER RH, HERMANS PE, et al. Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. J Hepatol 1993: 18: 185.
11. FALAGAS ME, SNYDMAN DR, GRIFFITH J, et al. CMV exposure from the donated organ is a risk factor for bacteremia in orthotopic liver transplant recipients. Clin Infect Dis 1996: 23: 468.
12. BANDO K, PARADIS IL, KOMATSU K, et al. Analysis of time-dependent risks for infection, rejection, death after pulmonary transplantation. J Thorac Cardiovasc Surg 1995: 109: 49.
13. ETTINGER NA, BAILEY TC, TRULOCK EP, et al. Cytomegalovirus infection and pneumonitis: Impact after isolated lung transplantation. Am Rev Respir Dis 1993: 147: 1017.
14. FALGAS ME, SNYDMAN DR, GRIFFITH J, et al. Effect of cytomegalovirus infection status on first-year mortality rates among orthotopic liver transplant recipients. Ann Intern Med 1997: 126: 275
15. PATEL R, SNYDMAN DR, RUBIN RH, et al. Cytomegalovirus prophylaxis in solid organ transplant recipients. Transplantation 1996: 61: 1279.
16. HIBBERD PL, TOLKOFF-RUBIN NE, CONTI D, et al. Preemptive ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus antibody-positive renal transplant recipients. Ann Intern Med 1995: 123: 18.
17. WINSTON DJ, WIRIN D, SHAKED A, BUSUTTIL RW. Randomized comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients. Lancet 1995: 345: 69.
18. STRATTA RJ, SHAEFER MS, CUSHING KA, et al. A randomized prospective trial of acyclovir and immune globulin prophylaxis in liver transplant recipients receiving OKT3. Arch Surgery 1992: 127: 55.
19. MARTIN FM, MANEZ P, LINDEN P, et al. A prospective randomized trial comparing sequential ganciclovir-high dose acyclovir to high-dose acyclovir for prevention of cytomegalovirus disease in adult liver transplant recipients. Transplantation 1994: 58: 779.
20. SALIBA FD, EYRAUD D, SAMUEL MF, et al. Randomized controlled trial of acyclovir for the prevention of cytomegalovirus infection and disease in liver transplant recipients. Transpl Proc 1993: 25: 1444.
21. SNYDMAN DR, WERNER BG, DOUGHERTY NN, et al. Cytomegalovirus immune globulin prophylaxis in liver transplantation. A randomized, double-blind, placebo controlled trial. Ann Intern Med 1993: 119: 984.
22. SNYDMAN DR, WERNER BG, DOUGHERTY NN, et al. and the Boston Center for Liver Transplantation CMVIG-Study Group. A further analysis of the use of cytomegalovirus immune globulin in orthotopic liver transplant patients at risk for primary infection. Transpl Proc 1994: (Suppl 1): 23.
23. SAS/STAT user's Guide, Version 6, 4th edition, SAS Institute Inc., Cary, NC, 1990.
24. GREGER B, VALLBRACHT A, KURTH J, et al. The clinical value of CMV prophylaxis by CMV hyperimmune serum in the kidney transplant patient. Transpl Proc 1986: 18: 1387.
25. FASSBINDER W, ERNST W, HANKE R, et al. Cytomegalovirus infection after renal transplantation: effect of prophylactic hyperimmunoglobulin. Transpl Proc 1986: 18: 1393.
26. SNYDMAN DR, WERNER BG, HEINZE-LACEY B, et al. Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 1987: 317: 1049.
27. CONTI DJ, FREED BM, GRUBER SA, et al. Prophylaxis of primary cytomegalovirus disease in renal transplant recipients. Arch Surg 1994: 129: 443.
28. STEINMULLER DR, NOVICK AC, STREEM SB, et al. Intravenous immunoglobulin infusions for the prophylaxis of secondary cytomegalovirus infection. Transplantation 1990: 49: 68.
29. SALIBA F, ARULNADEN JL, GUGENHEIM J, et al. CMV hyperimmune globulin prophylaxis after liver transplantation: a prospective randomized controlled study. Transpl Proc 1989: 21: 2260.
30. SNYDMAN DR, WERNER BG, TILNEY NL, et al. Final analysis of primary cytomegalovirus disease prevention in renal transplant recipients with a cytomegalovirus-immune globulin: comparison of the randomized and open-label trials. Transpl Proc 1991: 23: 1357.
31. WERNER BG, SNYDMAN DR, FREEMAN R, et al. Cytomegalovirus immune globulin for the prevention of primary CMV disease in renal transplant patients: analysis of usage under treatment IND status. The treatment IND study group. Transpl Proc 1993: 25: 1441.
32. ETTENGER RB, YADIN O. The potential role of therapeutic antibodies in the regulation of rejection. Transpl Proc 1995: 27(Suppl 1): 13.
33. METSELAAR H, WEIMAR W. Prevention of cytomegalovirus infection after organ transplantation with passive immunization. Beitr Infusionther 1992: 30: 198.
34. GLOWACKI LS, SMAILL FM. Use of immune globulin to prevent symptomatic cytomegalovirus disease in transplant recipients a meta-analysis. Clin Transpl 1994: 8: 10.
35. WITTES J, KELLY A, PLANTE K. Meta-analysis of CMV-IG studies for the prevention and treatment of CMV-infection in transplant patients. Transpl Proc 1996 (in press).
36. FALAGAS ME, SNYDMAN DR. Cytomegalovirus and mortality among liver transplant recipients in the 1990s. Ann Intern Med (in press) (letter).
37. SALIBA F, FARGES O, SAMUEL D, et al. Impact of cytomegalovirus on morbidity and mortality after liver transplantation. In Program and Abstracts Book, 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), San Francisco, CA, September 1995, abstract # H120, pp. 201.
38. DE OTERO J, GAVALDI J, MARGARIT C, et al. Does cytomegalovirus disease modify the patient survival after liver transplant? In Program and Abstracts Book, 36th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), New Orleans, Louisiana, September 1996, abstract # H5, pp. 164.